113 related articles for article (PubMed ID: 12115723)
1. Recovery of cellular E-cadherin precedes replenishment of estrogen receptor and estrogen-dependent proliferation of breast cancer cells rescued from a death stimulus.
Malaguti C; Rossini GP
J Cell Physiol; 2002 Aug; 192(2):171-81. PubMed ID: 12115723
[TBL] [Abstract][Full Text] [Related]
2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
3. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells.
Guvakova MA; Surmacz E
Exp Cell Res; 1997 Feb; 231(1):149-62. PubMed ID: 9056422
[TBL] [Abstract][Full Text] [Related]
5. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
Wang LH; Yang XY; Zhang X; Mihalic K; Xiao W; Farrar WL
Cancer Res; 2003 May; 63(9):2046-51. PubMed ID: 12727818
[TBL] [Abstract][Full Text] [Related]
6. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating Bcl-2 expression.
Wang L; Li Z; Wang C; Yang Y; Sun L; Yao W; Cai X; Wu G; Zhou F; Zha X
Arch Biochem Biophys; 2009 Jan; 481(1):116-22. PubMed ID: 18983973
[TBL] [Abstract][Full Text] [Related]
8. Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
Planas-Silva MD; Hamilton KN
Cancer Chemother Pharmacol; 2007 Sep; 60(4):535-43. PubMed ID: 17186241
[TBL] [Abstract][Full Text] [Related]
9. Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells.
Wang Q; Maloof P; Wang H; Fenig E; Stein D; Nichols G; Denny TN; Yahalom J; Wieder R
Exp Cell Res; 1998 Jan; 238(1):177-87. PubMed ID: 9457070
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
11. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
12. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry: a new approach for the molecular profiling of breast cancer.
Lostumbo A; Mehta D; Setty S; Nunez R
Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
[TBL] [Abstract][Full Text] [Related]
14. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.
Cos S; Fernández R; Güézmes A; Sánchez-Barceló EJ
Cancer Res; 1998 Oct; 58(19):4383-90. PubMed ID: 9766668
[TBL] [Abstract][Full Text] [Related]
15. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
16. Extraction-dependent effects of American ginseng (Panax quinquefolium) on human breast cancer cell proliferation and estrogen receptor activation.
King ML; Adler SR; Murphy LL
Integr Cancer Ther; 2006 Sep; 5(3):236-43. PubMed ID: 16880429
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
18. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression.
Mauro L; Catalano S; Bossi G; Pellegrino M; Barone I; Morales S; Giordano C; Bartella V; Casaburi I; Andò S
Cancer Res; 2007 Apr; 67(7):3412-21. PubMed ID: 17409452
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix, Rac1 signaling, and estrogen-induced proliferation in MCF-7 breast cancer cells.
Xie JW; Haslam SZ
Breast Cancer Res Treat; 2008 Jul; 110(2):257-68. PubMed ID: 17851761
[TBL] [Abstract][Full Text] [Related]
20. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]